Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Current and Projected Market Size of the Cannabis Pharmaceuticals Market Through 2034?
The size of the cannabis pharmaceuticals market has expanded significantly in the past few years. The market is estimated to increase from a value of $6.03 billion in 2024 to $9.43 billion in 2025, growing at a compounded annual growth rate (CAGR) of 56.4%. The growth experienced in the historical period can be credited to factors such as the growing legalization of medical cannabis, heightened awareness about the therapeutic benefits of cannabinoids, increased occurrence of chronic and neurological disorders, favorable regulatory structures, increased investments in pharmaceuticals, and a change in the public attitudes towards the use of cannabis in healthcare.
The expected expansion of the cannabis pharmaceuticals market in the coming years is significant, with predictions showing growth to $55.53 billion in 2029, increasing at a compound annual growth rate (CAGR) of 55.8%. This anticipated surge during the forecast period is largely due to factors such as rising regulatory approvals, broader understanding of the medicinal benefits of cannabis, its growing usage in managing pain and neurological disorders, increasing occurrence of chronic diseases, advancements in drug delivery systems, and the establishment of supportive reimbursement policies. Future trends include improvements in cannabinoid extraction processes, the development of specific drug delivery systems, the use of synthetic cannabinoid formulations, enhanced clinical trial methods, and the incorporation of artificial intelligence in drug research.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20723&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Cannabis Pharmaceuticals Market?
An increase in epilepsy instances is anticipated to fuel the expansion of the cannabis pharmaceuticals market. Epilepsy, a neurological disorder distinguished by recurrent, unwarranted seizures caused by irregular electrical activities in the brain, has seen a rise due to improved diagnosis, heightened awareness, as well as superior reporting. Additionally, factors like environmental, genetic, and lifestyle influences could be contributors. Cannabis pharmaceuticals, utilizing cannabinoids like CBD, have demonstrated potential in managing epilepsy. They can minimize the frequency and severity of seizures in patients who otherwise show minimal response to conventional anti-epileptic drugs. For Example, as reported by the European Brain Council, a non-profit organization based in Belgium, over 600 neurological disorders and nearly 300 psychiatric conditions plague millions worldwide, including 65 million epilepsy patients, as of April 2022. Additionally, according to the Alzheimer Society of Canada, a health charity situated in Canada, the estimates suggest that 771,939 Canadians will be suffering from dementia on January 1, 2025. This number is projected to reach nearly one million by 2030. Thus, the escalating epilepsy cases are boosting the cannabis pharmaceuticals market’s growth.
Which Key Market Segments Comprise the Cannabis Pharmaceuticals Market and Drive Its Revenue Growth?
The cannabis pharmaceuticalsmarket covered in this report is segmented –
1) By Product Type: Cannabinoid-Based Pharmaceuticals; Cannabis Extracts; Synthetic Cannabinoids
2) By Formulation Type: Capsules And Tablets; Oils And Tinctures; Topical Solutions
3) By Therapeutic Application: Cancer; Neurological Disorders; Pain Management
4) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
5) By End-User: Hospitals And Clinics; Rehabilitation Centers; Research Organizations
Subsegments:
1) By Cannabinoid-Based Pharmaceuticals: THC-Based Pharmaceuticals; CBD-Based Pharmaceuticals; Combination of THC and CBD Pharmaceuticals; Other Cannabinoid-Based Formulations
2) By Cannabis Extracts: Full-Spectrum Cannabis Extracts; Broad-Spectrum Cannabis Extracts; Isolate Cannabis Extracts (CBD Isolate)
3) By Synthetic Cannabinoids: Synthetic THC Analogues; Synthetic CBD Analogues; Synthetic Cannabinoid Receptor Agonists; Designer Synthetic Cannabinoids
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=20723&type=smp
Which Areas Are Leading Regions in the Cannabis Pharmaceuticals Market Expansion Across the Globe?
North America was the largest region in the cannabis pharmaceuticals market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cannabis pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theCannabis Pharmaceuticals Market Direction?
The primary players in the cannabis pharmaceuticals marketplace are honing in on crafting pioneering products such as sophisticated medical cannabis compounds. These are intended to address various medical scenarios and enhance patient recovery rates. Sophisticated medical cannabis compounds denote uniquely formulated cannabis-rooted products, tailored for a therapeutic application that incorporate accurate dosages of cannabinoids including THC and CBD. Take for instance, Canexis Pharma AG, a biomedical firm based in Switzerland, who in April 2024, obtained manufacturing and narcotics licenses from Swissmedic, specific for cannabis pharmaceuticals. These permissions facilitate the firm to manufacture top-quality medicinal active ingredients originating from CBD and THC, thus enhancing Canexis’s ability to cater to the surging requirement for medicinal cannabis in Switzerland and internationally. By securing these licenses, the firm illustrates its adherence to rigorous regulatory standards, escalating its dependability and capacity to contribute to the fast-paced evolution of the medical cannabis market.
View the full report here:
https://www.thebusinessresearchcompany.com/report/cannabis-pharmaceuticals-global-market-report
How Is the Cannabis Pharmaceuticals Market Conceptually Defined?
Cannabis pharmaceuticals are prescription-grade medications made from cannabis-derived compounds, designed to address particular health conditions and produced under strict clinical and regulatory standards. These pharmaceuticals utilize the therapeutic benefits of cannabinoids, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), to treat conditions including chronic pain, epilepsy, and multiple sclerosis.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20723
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model